Score Your Stock

US stock · figures in US dollars · scored on full-year results

Edwards Lifesciences Edwards Lifesciences Corporation Common Stock

EW · Healthcare · Medical Devices
Top 41% of scored stocks
OkayTop 41% of scored stocks
Weak Spot

Edwards Lifesciences scores 57/100 on fundamentals: in the top 41% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (100/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.

Best
Financial 100
Weakest
Price 0
  • Carries a Weak Spot flag

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 53.2b#223 of 503 in the S&P 500EPSUS$ 1.68P/E49.8×✗ vs sector median 29.6×P/B5.2×✗ vs sector median 3.7×Div yieldNo dividends paidBottom 12% in the S&P 50052w range · 82% of range74.6696.29
as of 31 Oct 2026

Nearby peers

Ranks #23 of 60 in Healthcare by score

#1Universal Health Services79#21McKesson59#22Agilent Technologies57
#23Edwards Lifesciences57
#24Zoetis57#25DaVita56

One-Minute Summary

Why Edwards Lifesciences scores 57

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

60
Why 60?
Pillar score: (1 + 2 + 0 + 2 + 1) = 6 of 10 points → 60
Return on Equity (ROE)10%Okay4-Year Revenue Growth+11%/yrStrong4-Year Profit Growth-11%/yrWeakNet Profit Margin18%StrongQuarterly Momentum+15%Okay
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↓ -29.5%Equity ↑ +78%ROE % 10.4%
Net ProfitEquityROE %
1.5b1.4b4.2b1.1b5.8b6.7b10.0b10.3b202220232024202526.2%21.1%41.8%10.4%

Revenue & Net Profit, with Net Margin

Revenue ↑ +35.9%Net Profit ↓ -29.5%Net Margin % 17.7%
RevenueNet ProfitNet Margin %
4.5b5.0b5.4b6.1b1.5b1.4b4.2b1.1b202220232024202534.1%28%76.7%17.7%

Sales grew about 35.9% over 4 years: customers keep spending more with this company.

Profit fell about 29.5% from where it was 4 years ago: the boom has cooled off.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +28.5%Net Profit ↓ -92.1%Net Margin % 13.9%
RevenueNet ProfitNet Margin %
1.4b1.4b1.4b1.5b1.6b1.6b1.6b1.7b3.1b384m358m333m291m91m381m242mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26226.6%27.7%25.3%21.7%18.7%5.8%23.1%13.9%
▲▬▬▼▼▼▲▼

Sales grew about 28.5% over the last 8 quarters: customers keep spending more with this company.

Profit fell about 92.1% over the last 8 quarters.

Why 100?
Pillar score: (2 + 2 + 2) = 6 of 6 points → 100
Debt-to-Equity0.1×StrongCurrent Ratio3.7×StrongInterest Coverage63.4×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt → +2%Equity ↑ +78%D/E 0.1×
Total DebtEquityD/E
691m685m700m705m5.8b6.7b10.0b10.3b20222023202420250.1×0.1×0.1×0.1×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +117.7%Current Liabilities ↑ +77.4%Current Ratio 3.7×
Current AssetsCurrent LiabilitiesCurrent Ratio
3.1b4.0b6.3b6.7b1.0b1.2b1.5b1.8b20222023202420253×3.4×4.2×3.7×
Why 75?
Pillar score: (0 + 2 + 2 + 2) = 6 of 8 points → 75
Dividend QualityNo dividends paidWeak
Payout ratio: 0%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +30.9%Free CF ↑ +40%
Operating CFFree CF
1.2b896m542m1.6b953m630m260m1.3b2022202320242025

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↑ +282.1%Short-Term Debt ↓ -3.9%Total Debt → +2%
CashShort-Term DebtTotal Debt
769m1.1b3.0b2.9b26m23m23m25m691m685m700m705m2022202320242025

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0%
DPS (cents)Yield %
000020222023202420250%0%0%0%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio49.8×WeakP/B Ratio5.2×WeakPEG Ration/m (growth not measurable)Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 94.37US$ 85.12US$ 75.87Oct '25Feb '26Jun '26Oct '26

The share price is up about 11.6% over the past year.

Why 50?
Pillar score: (1 + 1 + 2 + 2 + 0 + 0) = 6 of 12 points → 50
Earnings ConsistencyUnevenOkayDebt Trend (4yr)StableOkayShare Count Trend (4yr)-2%/yrStrongInventory vs Sales (4yr)-2 pp/yr vs salesStrongAsset Turnover Trend (4yr)-17.7%WeakQuarterly Consistency3 of 4 quarters downWeak
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +35.9%Inventory ↑ +28.6%Inv. % of Rev. 18.6%
RevenueInventoryInv. % of Rev.
4.5b5.0b5.4b6.1b876m904m1.1b1.1b202220232024202519.6%18%20%18.6%
Ranks #23 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#21McKesson59#22Agilent Technologies57
#23Edwards Lifesciences (you)57
#24Zoetis57#25DaVita56

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDiv yieldP/E RatioP/B RatioPEG Ratio
2025US$ 6.1bUS$ 1.1bUS$ 1.6bUS$ 1.3bUS$ -260.2mUS$ 2.9bUS$ 705.4mUS$ 24.5mUS$ 10.3bUS$ 6.7bUS$ 1.8bUS$ 13.7bUS$ 3.4bUS$ 1.1bUS$ 0.0m10%18%0.1×3.7×63.4×0%46.2×4.8×-
2024US$ 5.4bUS$ 4.2bUS$ 542.3mUS$ 259.9mUS$ -282.4mUS$ 3.0bUS$ 700.0mUS$ 23.4mUS$ 10.0bUS$ 6.3bUS$ 1.5bUS$ 13.1bUS$ 3.0bUS$ 1.1bUS$ 0.0m42%77%0.1×4.2×79.2×0%10.4×4.4×0.3
2023US$ 5.0bUS$ 1.4bUS$ 895.8mUS$ 629.5mUS$ -266.3mUS$ 1.1bUS$ 685.1mUS$ 22.9mUS$ 6.7bUS$ 4.0bUS$ 1.2bUS$ 9.4bUS$ 2.6bUS$ 903.5mUS$ 0.0m21%28%0.1×3.4×79.0×0%32.7×6.9×1.7
2022US$ 4.5bUS$ 1.5bUS$ 1.2bUS$ 953.4mUS$ -264.8mUS$ 769.0mUS$ 691.3mUS$ 25.5mUS$ 5.8bUS$ 3.1bUS$ 1.0bUS$ 8.3bUS$ 2.5bUS$ 875.5mUS$ 0.0m26%34%0.1×3.0×80.1×0%29.8×7.8×2.3